一种可解释的基于堆叠的方法来加速对抗糖尿病的预测
Farwa Arshad1, Saeed Ahmed1, Aqsa Amjad1
1School of Systems and Technology, University of Management and Technology, Lahore, 54770, Pakistan.
Analytical biochemistry
|April 26, 2024
概括
研究人员开发了STADIP,这是一个用于预测抗糖尿病 (ADP) 的计算工具. 这种方法有助于通过分析性质以改善血糖控制来识别新的糖尿病治疗方法.
科学领域:
- 计算生物学是一种计算生物学.
- 生物技术是生物技术.
- 生物信息学是一种生物信息学.
背景情况:
- 糖尿病是一种由高血糖症标志的慢性疾病,需要有效的管理策略.
- 目前的实验性疗法需要强大的方法来评估疗效.
- 计算工具为加速发现新的糖尿病治疗方法提供了一个有希望的途径.
研究的目的:
- 介绍STADIP,一种基于堆叠的组合预测器,用于识别抗糖尿病 (ADP).
- 利用机器学习来提高糖尿病管理中治疗性的预测.
主要方法:
- 开发了84个基线模型,使用了12个特征编码和7个机器学习技术.
- 采用两步特征选择 (XGB-SFS) 来优化预测性能.
- 将45个选定的特征集成到最终的混合模型中,使用元预测方法 (XGB分类器).
主要成果:
- 与个人基线模型相比,STADIP的预测性能优越.
- 在独立测试中获得了高精度 (0.954) 和马修的相关系数 (0.877).
- 堆叠组合方法有效地提高了ADP预测的准确性.
结论:
- STADIP是用于预测抗糖尿病的强大而准确的工具.
- 这种计算方法可以显著帮助研究人员发现新的治疗糖尿病.
- 这项研究强调了机器学习在促进糖尿病治疗研究方面的潜力.
相关概念视频
Glucagon-like Receptor Agonists
319
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
319
Insulin: Biosynthesis, Chemistry, and Preparation
374
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
374
Dipeptidyl Peptidase 4 Inhibitors
181
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Insulin Secretory Vesicles
4.9K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.9K
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154


